坦桑尼亚9-14岁女孩单剂HPV疫苗(DoRIS)与历史队列单剂HPV疫苗的免疫桥接分析:一项随机对照试验
该免疫桥接分析将坦桑尼亚DoRIS随机试验中单剂2价或9价HPV疫苗女孩的抗体几何平均浓度与历史队列CVT和IARC印度试验单剂受试者比较,24个月时HPV16和HPV18的GMC比值95%CI下限均大于0.50,非劣效性成立。作者认为年轻女孩单剂HPV疫苗可能提供足够保护。
要点
- DoRIS单剂2价疫苗组24个月HPV16 IgG GMC为22.9 IU/mL,CVT为17.7 IU/mL,GMC比值1.30(95%CI 1.00-1.68)。
- DoRIS单剂9价疫苗组24个月HPV16 IgG GMC为13.7 IU/mL,IARC印度试验为6.7 IU/mL,GMC比值2.05(95%CI 1.61-2.61)。
- 各疫苗HPV16和HPV18抗体GMC非劣效性均成立,作者认为单剂可能提供足够保护。
核心结论
- 年轻女孩接种单剂HPV疫苗可能提供足够保护以对抗持续性HPV感染,单剂方案可降低成本、简化疫苗递送并扩大疫苗可及性。
研究设计与样本
- 这是DoRIS开放标签随机对照试验的免疫桥接分析,2017年2月23日至2018年1月6日在坦桑尼亚姆万扎54所公立学校招募9-14岁健康HIV阴性女孩。
- 930名女孩按1:1:1:1:1:1随机分配至2价疫苗或9价疫苗的1剂、2剂或3剂组,每组155人;分析纳入单剂2价组154人(99%)和单剂9价组152人(98%)。
- 历史对照为CVT单剂2价疫苗受试者115人(中位年龄21岁[IQR 19-23])和IARC印度试验单剂4价疫苗受试者139人(中位年龄14岁[IQR 13-16])。
- 采用病毒样颗粒ELISA检测HPV16和HPV18 IgG抗体,GMC比值非劣效性预设为95%CI下限大于0.50。
主要发现
- 接种后24个月,HPV16 IgG GMC在DoRIS单剂2价组为22.9 IU/mL(95%CI 19.9-26.4;n=148),CVT为17.7 IU/mL(95%CI 13.9-22.5;n=97),GMC比值1.30(95%CI 1.00-1.68)。
- HPV16 IgG GMC在DoRIS单剂9价组为13.7 IU/mL(95%CI 11.9-15.8;n=145),IARC印度试验为6.7 IU/mL(95%CI 5.5-8.2;n=131),GMC比值2.05(95%CI 1.61-2.61)。
- HPV18 IgG GMC在DoRIS单剂2价组为9.9 IU/mL(95%CI 8.5-11.5;n=141),CVT为8.0 IU/mL(95%CI 6.4-10.0;n=97),GMC比值1.23(95%CI 0.95-1.60)。
- HPV18 IgG GMC在DoRIS单剂9价组为5.7 IU/mL(95%CI 4.9-6.8;n=136),IARC印度试验为2.2 IU/mL(95%CI 1.9-2.7;n=129),GMC比值2.12(95%CI 1.59-2.83)。
- 每种疫苗针对HPV16和HPV18的抗体GMC非劣效性均成立。
关键数值与推荐
- 非劣效性标准为GMC比值(DoRIS试验 vs 历史队列)95%CI下限大于0.50。
- HPV16:DoRIS单剂2价组 vs CVT GMC比值1.30(95%CI 1.00-1.68);DoRIS单剂9价组 vs IARC印度试验 GMC比值2.05(95%CI 1.61-2.61)。
- HPV18:DoRIS单剂2价组 vs CVT GMC比值1.23(95%CI 0.95-1.60);DoRIS单剂9价组 vs IARC印度试验 GMC比值2.12(95%CI 1.59-2.83)。
临床怎么用
- 作者认为年轻女孩单剂HPV疫苗可能提供足够保护,单剂方案可降低成本、简化疫苗递送并扩大疫苗可及性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) vaccines are given as a two-dose schedule in children aged 9-14 years, or as three doses in older individuals. We compared antibody responses after one dose of HPV vaccine in the Dose Reduction Immunobridging and Safety Study (DoRIS), a randomised trial of different HPV vaccine schedules in Tanzania, to those from two observational HPV vaccine trials that found high efficacy of one dose up to 11 years against HPV16 and HPV18 (Costa Rica Vaccine Trial [CVT] and Institutional Agency for Research on Cancer [IARC] India trial). METHODS: In this immunobridging analysis of an open-label randomised controlled trial, girls were recruited from 54 government schools in Mwanza, Tanzania, into the DoRIS trial. Girls were eligible if they were aged 9-14 years, healthy, and HIV negative. Participants were randomly assigned (1:1:1:1:1:1), using permutated block sizes of 12, 18, and 24, to one, two, or three doses of the 2-valent vaccine (Cervarix, GSK Biologicals, Rixensart, Belgium) or the 9-valent vaccine (Gardasil 9, Sanofi Pasteur MSD, Lyon, France). For this immunobridging analysis, the primary objective was to compare geometric mean concentrations (GMCs) at 24 months after one dose in the per-protocol population compared with in historical cohorts: the one-dose 2-valent vaccine group in DoRIS was compared with recipients of the 2-valent vaccine Cervarix from CVT and the one-dose 9-valent vaccine group in DoRIS was compared with recipients of the 4-valent vaccine Gardasil (Merck Sharp & Dohme, Whitehouse Station, NJ, USA) from the IARC India trial. Samples were tested together with virus-like particle ELISA for HPV16 and HPV18 IgG antibodies. Non-inferiority of GMC ratios (DoRIS trial vs historical cohort) was predefined as when the lower bound of the 95% CI was greater than 0·50. This study is registered with ClinicalTrials.gov, NCT02834637. FINDINGS: Between Feb 23, 2017, and Jan 6, 2018, we screened 1002 girls for eligibility, of whom 930 were enrolled into DoRIS and 155 each were assigned to one dose, two doses, or three doses of 2-valent vaccine, or one dose, two doses, or three doses of 9-valent vaccine. 154 (99%) participants in the one-dose 2-valent vaccine group (median age 10 years [IQR 9-12]) and 152 (98%) in the one-dose 9-valent vaccine group (median age 10 years [IQR 9-12]) were vaccinated and attended the 24 month visit, and so were included in the analysis. 115 one-dose recipients from the CVT (median age 21 years [19-23]) and 139 one-dose recipients from the IARC India trial (median age 14 years [13-16]) were included in the analysis. At 24 months after vaccination, GMCs for HPV16 IgG antibodies were 22·9 international units (IU) per mL (95% CI 19·9-26·4; n=148) for the DoRIS 2-valent vaccine group versus 17·7 IU/mL (13·9-22·5; n=97) for the CVT (GMC ratio 1·30 [95% CI 1·00-1·68]) and 13·7 IU/mL (11·9-15·8; n=145) for the DoRIS 9-valent vaccine group versus 6·7 IU/mL (5·5-8·2; n=131) for the IARC India trial (GMC ratio 2·05 [1·61-2·61]). GMCs for HPV18 IgG antibodies were 9·9 IU/mL (95% CI 8·5-11·5: n=141) for the DoRIS 2-valent vaccine group versus 8·0 IU/mL (6·4-10·0; n=97) for the CVT trial (GMC ratio 1·23 [95% CI 0·95-1·60]) and 5·7 IU/mL (4·9-6·8; n=136) for the DoRIS 9-valent vaccine group versus 2·2 IU/mL (1·9-2·7; n=129) for the IARC India trial (GMC ratio 2·12 [1·59-2·83]). Non-inferiority of antibody GMCs was met for each vaccine for both HPV16 and HPV18. INTERPRETATION: One dose of HPV vaccine in young girls might provide sufficient protection against persistent HPV infection. A one-dose schedule would reduce costs, simplify vaccine delivery, and expand access to the vaccine. FUNDING: UK Department for International Development/UK Medical Research Council/Wellcome Trust Joint Global Health Trials Scheme, The Bill & Melinda Gates Foundation, and the US National Cancer Institute. TRANSLATION: For the KiSwahili translation of the abstract see Supplementary Materials section.
引用
- Baisley K, Kemp TJ, Kreimer AR, et al. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial. Lancet Glob Health. 2022. PMID: 36113532. doi:10.1016/S2214-109X(22)00306-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。